X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ST-100 (vezocolmitide) is part of Stuart's PolyCol™ (PolyCol) platform of synthesized collagen mimetics, which target and treat disease damaged extracellular matrix (ECM) collagen. It is under phase 3 clinical development for the treatment of Dry Eye Disease.
Lead Product(s): Vezocolmitide
Therapeutic Area: Ophthalmology Product Name: ST-100
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ora, Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 29, 2023
Details:
Under the agreement, Glaukos gains exclusive worldwide rights to develop and commercialize Stuart's proprietary ST-113, a synthesized collagen mimetic peptide, drug candidate for neuroprotection in glaucoma.
Lead Product(s): ST-113
Therapeutic Area: Ophthalmology Product Name: ST-113
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Glaukos
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 18, 2023
Details:
ST-100 is part of Stuart's PolyCol™ (PolyCol) platform of synthesized collagen mimetics, which target and treat disease damaged extracellular matrix (ECM) collagen.
Lead Product(s): ST-100
Therapeutic Area: Ophthalmology Product Name: ST-100
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: AJU Pharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 03, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
